Neurology | Preclinical Developments

Voyager Therapeutics, Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations

Lead Product(s): Tau and Alpha-synuclein vectorized antibody

Therapeutic Area: Neurology Product Name: Alpha-synuclein vectorized antibody

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: AbbVie Inc

Deal Size: $250.9 million Upfront Cash: Undisclosed

Deal Type: Termination August 03, 2020

Details:

Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.

AC Immune

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

Lead Product(s): Anti-TDP-43 antibody

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2020

Details:

Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved this year in the Company’s cutting-edge therapeutic and diagnostic programs targeting TDP-43 – which are amongst the most comprehensive in the field.

Sangamo Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Lead Product(s): AAV based gene regulation therapy

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: $795.0 million Upfront Cash: $75.0 million

Deal Type: Collaboration July 30, 2020

Details:

Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), aim to develop gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders.

AxoProtego Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy

Lead Product(s): EQ-6

Therapeutic Area: Neurology Product Name: EQ-6

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2020

Details:

AxoProtego has licensed the rights for the worldwide development and commercialization of Ethoxyquin and its derivatives (including EQ-6, its lead compound) from The Johns Hopkins University.

Tonix Pharmaceuticals Holding Corp

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tonix Pharma Announces that Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Meeting

Lead Product(s): Oxytocin

Therapeutic Area: Neurology Product Name: TNX-1900

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 27, 2020

Details:

Preclinical results of TNX-1900 (oxytocin solution for intranasal delivery) will be presented in a poster at the American Academy of Neurology’s first-ever Sports Concussion Conference.

National Institute of Neurological Disorders

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

MetVital Joins National Institute of Neurological Disorders and Stroke (part of the NIH) in the Epilepsy Therapy Screening Program (ETSP)

Lead Product(s): Enol-oxaloacetate

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: MetVital

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 24, 2020

Details:

AEO, a patented molecule, is MetVital's lead clinical development drug candidate and has been approved for commercial Phase 2 testing of Glioblastoma multiforme, a malicious type of brain cancer, and the seizures caused by the cancer.

Encoded Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome

Lead Product(s): ETX101

Therapeutic Area: Neurology Product Name: ETX101

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: GV

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Series D Financing July 22, 2020

Details:

ETX101, Encoded's lead asset, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by FDA for the treatment of SCN1A+ Dravet Syndrome.

Orphazyme

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson’s Disease Research

Lead Product(s): Arimoclomol

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Michael J. Fox Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 17, 2020

Details:

Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).

Knopp Biosciences LLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

Lead Product(s): KB-3061

Therapeutic Area: Neurology Product Name: KB-3061

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

Knopp is advancing the development of KB-3061 as a potential precision medicine for KCNQ2-EE, a rare genetic disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay.

Tranquis Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases

Lead Product(s): TQS-168

Therapeutic Area: Neurology Product Name: TQS-168

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Remiges Ventures

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing July 09, 2020

Details:

The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorders.

Find

Find Novel Neurology Drugs in Preclinical Development

Preclinical

Product Type

Companies

Voyager Therapeutics, Inc

Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations

AC Immune

AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration

Sangamo Therapeutics

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

AxoProtego Therapeutics

AxoProtego Therapeutics Announces Novel Investigational Agent for Chemotherapy-Induced Peripheral Neuropathy

Tonix Pharmaceuticals Holding Corp

Tonix Pharma Announces that Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Meeting

National Institute of Neurological Disorders

MetVital Joins National Institute of Neurological Disorders and Stroke (part of the NIH) in the Epilepsy Therapy Screening Program (ETSP)

Encoded Therapeutics

Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome

Orphazyme

Orphazyme to Collaborate with The Michael J. Fox Foundation on Parkinson’s Disease Research

Knopp Biosciences LLC

Knopp Biosciences Receives Rare Pediatric Disease Designation for Kv7 Activator KB-3061 for Treatment of KCNQ2 Epileptic Encephalopathy

Tranquis Therapeutics

Tranquis Therapeutics Launches with $30 Million Series A Funding to Advance Novel Immuno-Neurology to Treating Neurodegenerative Diseases